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The cell cycle of eukaryotic ells is strictly regulated. This regulation is performed by a serine/threonine kinase. The different functions of this kinase 
in the cell cycle are modulated by different cyclins, which fluctuate in concentration (‘cycle’) during the different stages of the cell cycle. Using yeast 
as a model organism we show here that the activity of the multifunctional proteinase, the proteasome, is directly connected to the function of the 
mitotic cyclin Clb2. Our studies indicate that the proteasome is the proteolytic regulator of this cyclin and thus a central regulator of the cell cycle. 
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1. INTRODUCTION 
The proteasome is an essential, multisubunit complex 
highly conserved from yeast to man. It consists of a 20s 
particle, which is integrated as a core unit into a 26s 
complex (for reviews, see [ 1,2]). The proteinase complex 
harbors at least three different major proteolytic activi- 
ties and the enzyme has been found to be located in the 
cytoplasm and the nucleus of cells (for reviews, see [l]). 
With the aid of yeast mutants defective in proteolytic 
functions of the proteasome its central role in the prote- 
olysis of ubiquitinated, short-lived and not properly as- 
sembled proteins has been discovered [3-91. The accu- 
mulating data on the involvement of the proteasome in 
the degradation of highly regulated as well as regulatory 
active proteins ([lo,1 11, Schork, S., Bee, G., Thumm, M. 
and Wolf, D.H., submitted) leads to the idea that the 
proteasome is the central cytoplasmic and nuclear pro- 
tease implicated in the degradation of all short-lived 
proteins. As expected, severe alterations within a pro- 
teinase complex fulfilling such central functions will 
lead to inviability of the cells. This has been demon- 
strated for the deletion of several subunits of the yeast 
proteasome; cells stop growing and die [3,6,7]. 
G,/S (called START) and the G,/M transition borders 
(for reviews, see [12-141). The kinase activity is regu- 
lated by a class of proteins called cyclins. Most of the 
cyclins are very unstable and only present at a particular 
phase of the cell cycle (for reviews, see [12-141. In yeast 
three cyclins (Clnl, Cln2 and Cln3) have been found to 
be essential for START [15-181, (for review, see [13]). 
A family of B-type cyclins has been found to act during 
S-phase or to be necessary for formation and function 
of the mitotic apparatus [19-221, (for review, see [13]). 
Of the four B-type cyclins that act in mitosis (Clbl, 
Clb2, Clb3 and Clb4) Clb2 is essential [13]. 
The cell cycle is a highly regulated event. All steps of 
the progression through the cell cycle have to be rigor- 
ously controlled (for reviews, see [12-141). It is gradu- 
ally emerging that in all cells a serine/threonine kinase, 
encoded by the CDC28 gene in yeast, is central to the 
control of the cell cycle. It is thought that the kinase 
activity is the key feature which mediates passage of 
cells through the two predominant control points at the 
In Xenupus an abrupt ubiquitin-dependent destruc- 
tion of the B-type cyclins has been observed which is 
mediated by a conserved sequence towards their amino 
termini called destruction box [23]. All four mitotic Clb 
cyclins of yeast contain sequences imilar to the Xen- 
opus B-type cyclin destruction box and deletion of this 
sequence in CLB2 causes stabilization of the protein 
[13,24]. The up to now discovered in vivo role of the 
proteasome in rapidly degrading non-assembled [8] 
ubiquitinated [3-71, short-lived [4,5] and metabolically 
regulated ([lo,1 l] Schork, S., Bee, G., Thumm, M. and 
Wolf, D.H., submitted) proteins led us to the idea, that 
the enzyme complex might also be involved in cyclin 
degradation and thus cell cycle regulation. We therefore 
tested the influence of the proteasome on the mitotic 
cyclin Clb2. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
*Corresponding author. Fax: (49) (711) 685 4392. 
All enzymes used in DNA manipulation were obtained from 
Boehringer-Mannheim (Germany). Yeast nitrogen base without 
amino acids was purchased from Difco (Detroit, USA). All other 
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chemicals were obtained from Pharmacia (Freiburg, Germany), Roth 
(Karlsruhe, Germany), Merck (Darmstadt, Germany) and Serva (Hei- 
delberg, Germany). 
2.2. Media 
E. coli strains were grown in LB [25] medium with or without 
ampicillin (50 &ml). Complete minimal (CM) dropout medium and 
mineral (MV) medium were prepared according to Ausubel et al. [26]. 
CM dropout medium contained 0.67% yeast nitrogen base without 
amino acids and 2% glucose or galactose supplemented with adenine 
and amino acids. MV medium contained 0.67% yeast nitrogen base 
without amino acids, 2% glucose and supplements required by 
auxotrophic strains. 
2.3. Strains 
E. coli strain used was: DH5a {F endA recA1 gyrA96 thid(argF- 
IacZ YA) U169 (fBadlacZdMlS)T hsdRl7 supE44 relA1) [27]. 
All yeast strains were derivatives of strain WCG4a (MATa his3- 
11.15 ura3 let&3,112 can GAL) [7]. The isogenicprel-I mutant strain 
was constructed by gene replacement of the wild type gene with the 
mutant allele prel-I [7]. The used yeast strains were: YBRl [MATa 
ura.3 his3-II.15 k&-3,112 can GAL (URA3)], YBR2 [MATa ura3 his3- 
II,15 leu2-3,112 can GAL (GALI-CLB2 W&43)], YBR3 [MATaprel- 
I ura3 hW-11.15 leu2-3,112 can GAL (CJRA3)], YBR4 [MATa prel-I 
ura3 his3-II,15 let&3.112 can GAL (GALI-CLB2 URA3)]. 
2.4. Molecular biological techniques and plasmids 
Purification, restriction, ligation, analysis of DNA and transforma- 
tion of E. coli were carried out according to standard procedures [25]. 
For transformation of Saccharomyces cerevisiae a protocol modtied 
according to [3] was followed. The CLB2 gene was excised from 
plasmid pRK172 kindly provided by Kim Nasmyth and inserted into 
plasmid pBMl50 (CEN4 ARSI URA3 ampR GAL1 GALIO) [28]. 
Plasmid pBRO1 was constructed as follows: The CLB2 gene was ex- 
cised from plasmid pRK172 using NdeI and HindIII. The overlapping 
ends of the resulting 1.4 kb fragment were filled with Klenow Polym- 
erase I to yield a blunt end fragment. pBM150 was cut with BamHI 
and the overlapping ends were filled with Klenow Polymerase I. The 
1.4 kb fragment containing CLB2 was blunt-end ligated into the filled 
BamHI site of pBMl50. 
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.The yeast strains were transformed with the centromere plasmids 
pBMl50 (URA3) and pBROlji;AL1-CLB2 URA3) expressing CLB2 
under control of the galactose inducible GAL1 promoter. 
2.5. Growth conditions 
Wild-type and mutant strains carrying the CLB2 expressing plasmid 
were grown to stationary phase in CM dropout medium containing 
2% glucose at 30°C. Wild type and mutant strains with and without 
plasmid pBM150 or plasmid pBRO1 were grown in identical fashion. 
Cells were diluted 1:lOOO in CM dropout medium containing 2% 
galactose and incubated over 72 h at 3O’C. Optical density was meas- 
ured at 578 nm. 
3. RESULTS AND DISCUSSION 
Monitoring cellular growth is the most sensitive assay 
to detect functions of essential proteins and their inter- 
action in the cell. The use of yeast mutants defective in 
the proteolytic activity of the proteasome should make 
possible the elucidation of any link existing between 
cyclin Clb2 function and proteasome action. Pro- 
teasome mutant cells defective in the PREI gene, carry- 
ing an amino acid exchange at position 142 (Ser-Phe) 
(alleleprel-I) show a major defect in the chymotrypsin- 
like activity of the enzyme complex but exhibit an only 
rather minor growth phenotype at 30°C [3,7]. This is in 
contrast to a prel deletion mutant which arrests growth 
in a budded state [6]. 
It has been shown that expression from the GAL1 
promoter of a single copy of the wild type CLB2 gene 
is tolerated by cells when grown on galactose, while 
expression of four copies of the gene is lethal. Also 
expression of a mutant CLB2 gene lacking the destruc- 
tion box leading to a stable Clb2 protein, which cannot 
be degraded any more is lethal [13,24]. This finding 
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Fig. 1. Growth of wild-type and mutant cells defective in the chymotrypsin-like activity of the proteasome carrying an extra copy of the mitotic 
cyclin CLBZ. Cells were grown as indicated in section 2. (A) Growth of wild type cells YBRl [MATa ura3 his3-II,IS leu2-3,112 can GAL (URA3)] 
carrying the centromere plasmid pBMI50 and YBR2 [MATa ura.3 his3-Il.15 leu2-3,112 can GAL (GALI-CLB2 URA3)] carrying the centromere 
plasmid pBRO1 into which the CLB2 gene under the control of the GAL1 promotor is inserted. (B) Growth of proteasome mutant cells YBR3 
[MATa prel-lura3 hir3-II,15 let&3,112 can GAL (URA3)] carrying the centromere plasmid pBMl50 and YBR4 [MATa prel-I ura3 his3-II.15 
leu2-3,112 can GAL (GALI-CLB2 URA3)] carrying the centromere plasmid pBRO1 which contains the CLB2 gene under the control of the GAL1 
promotor. 
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implies that growth of cells is very sensitive to the 
amount of cyclin Clb2 in the cell. It thus can be rea- 
soned that a defect in the proteinase defective in degra- 
dation of Clb2 should lead to a growth arrest of cells 
due to increased accumulation of this cyclin. We there- 
fore transformed isogenic wild type and prel-1 mutant 
cells with a centromere plasmid carrying the CLB2 gene 
under the control of the GAL1 promoter. Wild-type and 
mutant cells were pre-grown in glucose containing me- 
dium and then transferred onto galactose medium to 
derepress the Clb2 protein. Expression of the extra copy 
of CLB2 from the plasmid in wild type cells affects 
growth of cells to some extent, but is still tolerated (Fig. 
IA). In contrast, expression of the extra copy of CLB2 
in the proteasome mutant cells completely abolishes 
growth (Fig. 1B). These data clearly demonstrate a link 
between cyclin Clb2 action in the cell and the defect in 
the chymotrypsin-like activity of the proteasome. The 
growth arrest of prel-1 mutant cells expressing an extra 
copy of CLB2 is due to an enhanced level of Clb2 which 
is most likely caused by the inability of the defective 
proteasome to degrade the extra amount of Clb2, The 
results furthermore imply that there is no inactivation 
step of Clb2 prior to its proteasome mediated disap- 
pearance, indicating that the protease complex is the 
central regulator of this cyclin and thus of the cell cycle. 
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